Neurocrine Biosciences, Inc.
A neuroscience-focused biopharmaceutical company that makes medicines for brain and nervous-system conditions, including INGREZZA for tardive dyskinesia and Huntington's chorea, and CRENESSITY for a rare adrenal disorder called CAH. It was founded in 1992 by two scientists from the Salk Institute and Stanford to explore the link between the brain and the endocrine system. The name "Neurocrine" comes from the scientific term for how nerve cells release chemical messengers—fitting for a company born from research on stress hormones.
Granted 730.7K · Sold 748.7K
Granted 237.5K · Sold 243.1K
Granted 90.2K · Sold 105.0K
Granted 5.0K · Sold 8.0K
Granted 300.3K · Sold 295.7K
Granted 125.0K · Sold 147.3K
Granted 115.0K · Sold 146.4K
Granted 114.2K · Sold 95.3K
Granted 73.4K · Sold 92.7K
Granted 29.6K · Sold 41.9K
Granted 95.4K · Sold 87.1K
Granted 116.6K · Sold 161.3K
Granted 144.8K · Sold 121.6K
Granted 57.1K · Sold 39.4K
Granted 120.4K · Sold 123.8K
Granted 65.4K · Sold 55.0K
Granted 23.8K · Sold 53.7K
Granted 6.9K
Granted 4.8K
Granted 5.2K · Sold 1.1K
Granted 23.2K · Sold 20.4K
Granted 3.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Gorman Kevin CharlesDirector · 43 transactions | +15.9% | 511.3K | 730.7K | — | 748.7K |
| Gano KyleChief Executive Officer, Director · 49 transactions | +49.2% | 146.3K | 237.5K | — | 243.1K |
| Lyons Gary ADirector · 24 transactions | -42.8% | 122.1K | 90.2K | — | 105.0K |
| Grigoriadis Dimitri E.Chief Research Officer · 3 transactions | +0.8% | 82.3Kas of Oct 2021 | 5.0K | — | 8.0K |
| Benevich EricChief Commercial Officer · 62 transactions | +304.9% | 63.2K | 300.3K | — | 295.7K |
| Lippoldt DarinChief Legal Officer · 72 transactions | +95.1% | 54.7K | 125.0K | — | 147.3K |
| Cooke JulieChief Human Resources Officer · 68 transactions | +289.4% | 45.1K | 115.0K | — | 146.4K |
| Rastetter William HDirector · 17 transactions | +76.5% | 43.7K | 114.2K | — | 95.3K |
| Abernethy MattChief Financial Officer · 42 transactions | +272.4% | 42.8K | 73.4K | — | 92.7K |
| Lloyd-Smith MalcolmChief Integration Officer · 14 transactions | +167.9% | 42.3Kas of Feb 2023 | 29.6K | — | 41.9K |
| Pops Richard FDirector · 20 transactions | +28.1% | 37.8K | 95.4K | — | 87.1K |
| Roberts EiryChief Medical Officer · 48 transactions | +124.9% | 35.6Kas of Feb 2025 | 116.6K | — | 161.3K |
| Onyia JudeChief Scientific Officer · 39 transactions | — | 23.4K | 144.8K | — | 121.6K |
| Delaet IngridChief Regulatory Officer · 65 transactions | — | 16.2K | 57.1K | — | 39.4K |
| Sherwin Stephen ADirector · 25 transactions | -41.4% | 15.9K | 120.4K | — | 123.8K |
| Morrow George JDirector · 9 transactions | — | 10.4K | 65.4K | — | 55.0K |
| Boyer David W.Chief Corp. Affairs Officer · 42 transactions | — | 7.8K | 23.8K | — | 53.7K |
| Mercier JohannaDirector · 3 transactions | — | 6.9K | 6.9K | — | — |
| Poon Christine ADirector · 2 transactions | — | 4.8K | 4.8K | — | — |
| Sharp ShaliniDirector · 4 transactions | — | 4.1K | 5.2K | — | 1.1K |
| Norwalk Leslie VDirector · 12 transactions | — | 2.8K | 23.2K | — | 20.4K |
| Keswani Sanjay ChandruChief Medical Officer · 2 transactions | — | 1.5K | 3.2K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 5 years: -2.59M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.